ResMed (RMD) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for ResMed (NYSE: RMD):

• 3/15/2025 – ResMed was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 3/7/2025 – ResMed was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 3/5/2025 – ResMed had its price target lowered by analysts at Stifel Nicolaus from $250.00 to $240.00. They now have a “hold” rating on the stock.
• 3/5/2025 – ResMed was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating.
• 1/31/2025 – ResMed was upgraded by analysts at UBS Group AG from a “hold” rating to a “strong-buy” rating.
• 1/31/2025 – ResMed had its price target raised by analysts at JPMorgan Chase & Co. from $270.00 to $286.00. They now have an “overweight” rating on the stock.
• 1/31/2025 – ResMed had its price target raised by analysts at KeyCorp from $266.00 to $280.00. They now have an “overweight” rating on the stock.
• 1/31/2025 – ResMed had its price target raised by analysts at Piper Sandler from $252.00 to $260.00. They now have a “neutral” rating on the stock.
• 1/31/2025 – ResMed had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/16/2025 – ResMed is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “buy” rating on the stock.

ResMed Stock Performance

Shares of NYSE:RMD traded up $0.30 during midday trading on Monday, hitting $224.46. The stock had a trading volume of 803,556 shares, compared to its average volume of 964,728. The company has a market capitalization of $32.97 billion, a PE ratio of 26.50, a P/E/G ratio of 1.53 and a beta of 0.74. The stock has a 50 day moving average price of $236.30 and a two-hundred day moving average price of $239.80. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 1 year low of $172.19 and a 1 year high of $263.05.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, equities analysts predict that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date is Thursday, February 13th. ResMed’s dividend payout ratio is currently 25.03%.

Insider Buying and Selling

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares in the company, valued at approximately $18,695,249.98. The trade was a 2.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kaushik Ghoshal sold 9,745 shares of ResMed stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the transaction, the insider now owns 9,725 shares of the company’s stock, valued at approximately $2,327,289.75. The trade was a 50.05 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,940 shares of company stock valued at $9,164,385. Corporate insiders own 0.71% of the company’s stock.

Hedge Funds Weigh In On ResMed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of ResMed by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 18,173,462 shares of the medical equipment provider’s stock valued at $4,156,089,000 after buying an additional 160,590 shares during the last quarter. State Street Corp raised its position in shares of ResMed by 1.9% in the third quarter. State Street Corp now owns 6,261,633 shares of the medical equipment provider’s stock valued at $1,528,590,000 after buying an additional 116,918 shares during the last quarter. Geode Capital Management LLC raised its position in shares of ResMed by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 3,944,084 shares of the medical equipment provider’s stock valued at $899,860,000 after buying an additional 85,270 shares during the last quarter. Invesco Ltd. raised its position in shares of ResMed by 32.2% in the fourth quarter. Invesco Ltd. now owns 2,325,009 shares of the medical equipment provider’s stock valued at $531,706,000 after buying an additional 566,046 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of ResMed by 20.6% in the fourth quarter. Northern Trust Corp now owns 1,702,590 shares of the medical equipment provider’s stock valued at $389,365,000 after buying an additional 290,664 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company’s stock.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.